BPI-572270

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameBPI-572270
Drug Alias NameBPI-572270
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGTPase Ras inhibitors
TargetsGTPase Ras
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBetta Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHangzhou Jingyao Biotechnology Co LtdBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A